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Abstract Delirium is a neuropsychiatric syndrome
characterized by a sudden and global impairment in con-
sciousness, attention and cognition. It is particularly frequent
in elderly subjects with medical or surgical conditions and is
associated with short- and long-term adverse outcomes. The
pathophysiology of delirium remains poorly understood as it
involves complex multi-factorial dynamic interactions
between a diversity of risk factors. Several conditions
associated with delirium are characterized by activation of
the inflammatory cascade with acute release of inflammatory
mediators into the bloodstream. There is compelling
evidence that acute peripheral inflammatory stimulation
induces activation of brain parenchymal cells, expression
of proinflammatory cytokines and inflammatory mediators
in the central nervous system. These neuroinflammatory
changes induce neuronal and synaptic dysfunction and
subsequent neurobehavioural and cognitive symptoms.
Furthermore, ageing and neurodegenerative disorders
exaggerate microglial responses following stimulation
by systemic immune stimuli such as peripheral inflamma-
tion and/or infection. In this review we explore the
neuroinflammatory hypothesis of delirium based on recent
evidence derived from animal and human studies.
Introduction
Delirium is a common neuropsychiatric syndrome clinically
characterized by a sudden onset and transient impairment
of consciousness and attention, with consecutive global
disturbance in cognition and behaviour. It affects predom-
inantly elderly subjects, with reported rates depending on
the sample and setting considered, being associated with
both short- and long-term adverse outcomes [94]. Thus, in
medical in-patient settings, the occurrence rate per admis-
sion is 11–42% [125]. In elective orthopaedic surgery the
incidence of postsurgical delirium ranges from 9 to 28%
[145]. Higher rates are seen in emergent hip fracture surgery
in which a large proportion of patients present with pre-
operative (4–36%) or post-operative delirium (up to 53%)
[19]. Post-operative delirium after cardiac surgery varies
from 2 to 57% according to the procedure, type of patients
and study methodology [22, 138]. In the context of sepsis,
delirium affects 9–71% of patients [37].
As with other neuropsychiatric disorders, the patho-
physiology of delirium remains poorly understood for a
number of reasons. First, the core features of delirium
(impaired level of consciousness and inattention) are dif-
ficult to define and to operationalize. Secondly, the protean
nature of delirium with respect to clinical symptoms,
severity and evolution challenges its recognition. Thirdly,
delirium has significant aetiological complexity reflecting
the dynamic interaction of multiple environmental and
individual factors. Finally, the inaccessibility of the central
nervous system (CNS) limits the exploration of the neuro-
biological correlates of the high integrative cognitive
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functions globally affected during delirium. Not surprisingly,
despite its clinical relevance, delirium has been a relatively
neglected area of research. However, considering that
delirium is a syndrome in which the link between brain and
body is most clear, ongoing advances in the understanding
of the interaction between the CNS and peripheral organs
through bloodstream herald important breakthroughs in the
study of its pathophysiology.
In this study we explore the contribution of the neuroin-
flammatory pathway to delirium. First, evidence associating
systemic inflammation with delirium is presented. Then, we
review the sequence of events explaining the relation
between acute systemic inflammatory stimulation and
delirium. Given the absence of neuropathological studies in
humans during the acute phase of delirium, animal models
provide the best available opportunity to study the neuro-
biological correlates of acute cognitive and behavioural
dysfunction following systemic inflammation. Whenever
possible, evidence obtained from human studies is dis-
cussed. Studies evaluating the effect of the ageing process
and neurodegeneration are also analysed in order to eluci-
date how these two known major risk factors for delirium are
involved in its pathophysiology. Finally, we present some
future perspectives on how these concepts can be useful to
develop new therapeutic measures to prevent delirium.
Taken together, these data provide a framework with heu-
ristic value to guide new approaches in the study of delirium.
Delirium concept
Clinical definition of delirium
Following the landmark work of Engel and Romano [42],
delirium has been conceptualized as a reversible state of
cerebral insufficiency comparable to the more familiar
concepts of renal or hepatic insufficiency. Although this
clinical syndrome was one of the first mental illnesses to be
recognized, its nosologic classification remains a continu-
ally evolving process. This is reflected in the scientific
literature by the use of a confusing plethora of terms refer-
ring to conditions that are embraced in the concept of
delirium as defined in the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV-TR) [5] or in the tenth edition
of the International Statistical Classification of Diseases and
Related Health Problems [146]. Often, different labels are
used specifically in some settings to describe the condition at
a clinical (e.g. acute confusional state) or pathophysiological
level (e.g. encephalopathy and acute brain failure). This
reveals both the multifaceted nature of delirium and the lack
of a consistent approach to this syndrome.
Currently, delirium is defined in DSM-IV-TR [5] by the
presence of disturbed consciousness (i.e. reduced clarity of
awareness of the environment with reduced ability to focus,
to sustain, or to shift attention) and a change in cognition
(such as memory deficit, disorientation, or language distur-
bance) or the development of a perceptual disturbance that is
not better accounted for by a pre-existing, established or
evolving dementia. The disturbance develops over a short
period of time (usually hours to days) and tends to fluctuate
during the course of the day. There is evidence from clinical
history, physical examination, and/or laboratory findings
that the disturbance is caused by direct physiological con-
sequences of a general medical condition [5].
In addition to these core symptoms, associated clinical
findings include disturbance in psychomotor function,
speech (thought process), sleep-wake cycle and mood. In
clinical practice, it is common to classify delirium as: (a)
hypoactive subtype, characterized by reduced alertness,
sedation and reduction of motor activity; (b) hyperactive
form, associated with hyper-vigilance, psychotic features
(e.g. hallucinations and delusions) and agitation; and (c) a
more prevalent, mixed subtype with overlapping features
of the previous two forms. There is a lack of consensus
about the definition of each subtype [33] and whether they
have different underlying aetiology and pathophysiology
[127]. However, there is growing evidence that hypoactive
delirium is associated with worse outcomes compared to
the other subtypes in elderly patients with dementia [147].
Pathophysiology of delirium
The pathophysiology of delirium involves the interplay
between predisposing, precipitating and protective factors
(Fig. 1). This model has been globally supported by numerous
studies in medical and surgical samples which have identified
several risk factors for delirium [22, 32, 69] (Table 1). Results
from these studies are difficult to summarize and generalize
because they involve different settings, measurements and
methodologies. However, most consistently reported vari-
ables across studies include: dementia, medical illness,
advanced age, abnormal blood urea nitrogen/creatinine ratio,
abnormal sodium or potassium level, alcohol abuse, sensory
impairment, and medications [40]. To reduce the analysis
heterogeneity, it is useful to differentiate studies according to
the setting (e.g. medical or surgical). Additionally, cardiac
surgery has been classically distinguished from non-cardiac
surgery as they differ with respect to factors with specific
effects on pathophysiology of delirium such as extra-corpo-
real circulation or vascular dysfunction (Table 1B, C). Some
studies have tried to determine the magnitude of risk associ-
ated with certain factors in order to establish the likelihood of
delirium occurrence. For example, Inouye et al. [69] devel-
oped a four-factor model for risk stratification in medical
patients in which presence of 1 or 2 factors had a 4.7-fold
increase in risk of delirium, while having 3 or 4 factors was
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associated with a 9.5-fold risk (Table 1A). When applied to a
non-cardiac surgical sample, this model proved to have good
reliability [70].
Consequently, from a pathophysiological point of view, it
is possible to conclude that in most cases of delirium there
is interaction of multiple precipitating and predisposing
factors, each one increasing the risk only marginally. While
providing a general view about the pathogenesis of delirium,
this does not elucidate the particular aetiological role of
each risk factor. Given the small individual effect sizes
of the several identified risk factors, delirium pathophysi-
ology is likely to involve the interaction of multiple
systems eliciting neurochemical abnormalities and brain
dysfunction. Thus, cholinergic dysfunction has long been
recognized to be involved in delirium pathophysiology
and has been proposed as a ‘‘final pathway’’ to delirium
regardless of the initial insult [133]. Other proposed
hypothesis for delirium pathophysiology includes decreased
oxidative metabolism, dysfunction of other neurotransmit-
ters (dopamine, norepinephrine, glutamate, serotonin, and
GABA), abnormal signal transduction, changes in blood-
brain barrier (BBB) permeability, endocrine abnormalities
and increased inflammatory response [87].
Clinical conditions with systemic inflammatory
reactions to induce delirium
Systemic inflammation is a prominent feature of numerous
medical and surgical conditions associated with delirium,
particularly when they involve tissue destruction and/or
infection (Table 2). Thus, delirium is a frequent manifes-
tation of a multiorganic dysfunction in the context of sepsis
[124], a presenting clinical feature of underlying urinary
tract infection or pneumonia (especially in demented
elderly patients) or a complication following a major sur-
gical procedure [102].
Peripheral infection activates the inflammatory cascade
following direct recognition of specific components of
microorganisms, such as lipopolysaccharide (LPS) in gram-
negative bacteria, by resident and circulating phagocytes.
A myriad of factors, such as tissue damage, blood loss,
pain and anaesthetics can influence the function of immu-
nocompetent cells and production of inflammatory
mediators [78]. Even in a sterile setting, inflammation can
be triggered following tissue destruction with the release of
endogenous ligands, including heat shock proteins, hyalu-
ronan, b-defensin and uric acid crystals which will activate
similar innate receptor pathways [8]. Proinflammatory
cytokines produced by resident macrophages and mono-
cytes, including tumour necrosis factor alpha (TNF-a) and
interleukin (IL)-1, will, in turn, stimulate the expression of
other mediators responsible for the recruitment of addi-
tional inflammatory cells to the injured site. Thus, what
initially can be a localized immune reaction spreads to a
generalized, systemic response with increased levels of
cytokines in the circulation [12, 76] (Table 2). In cardiac
surgery, cardiopulmonary bypass appears to be a major
factor for activation of complement and secretion of
proinflammatory cytokines contributing to post-operative
Fig. 1 Multifactorial model
of delirium
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multi-organ dysfunction [6]. Reversely, off-pump proce-
dures are associated with a lesser degree of plasmatic
inflammatory mediators and improved function of major
organs and post-operative cognitive performance [35].
Elevated levels of peripheral inflammatory mediators also
correlate with post-operative organ dysfunction in non-
cardiac surgical procedures [53].
In many other medical or surgical conditions, in which
delirium is a common occurrence, the release and production
of pro-inflammatory mediators into the circulation is part of
the pathophysiological process (Table 2). The extent to
which a certain condition activates the inflammatory cascade
depends on several factors, namely the intensity of physical/
surgical trauma and the likelihood of certain procedures to
promote the release and diffusion of inflammatory mediators
through the bloodstream (e.g. highly vascularized organs)
[114]. Evidence directly implicating acute systemic inflam-
mation in the occurrence of delirium comes from a study in
which blood levels of IL-6 and IL-8 were higher in patients
with post-operative delirium than in patients without delir-
ium [140]. However, the clinical correlate of the peripheral
inflammatory reaction, particularly to what extent it con-
tributes to neuropsychiatric symptoms, has remained largely
unexplored.
Effects of acute systemic inflammation in the brain
From acute systemic inflammation
to neuroinflammation
It is now well established that CNS resident cells react to the
presence of peripheral immune signals, leading to production
of cytokines and other mediators in the brain, cell proliferation
and activation of hypothalamus–pituitary–adrenal axis
through a complex system of interactions [31]. This innate
response constitutes an important adaptive advantage because
it coordinates a central response to combat acute peripheral
infection. Several pathways involved in this communication
include: (a) direct recognition of pathogenic signals or
inflammatory mediators in areas where BBB is altered or
absent; (b) energy-dependent transport systems for cytokines
in the BBB or second messengers actively produced in the
BBB; (c) detection of peripheral immune activation by spe-
cialized sensory nerves carrying information into the brain via
autonomic nervous system [63].
Disruption of blood-brain barrier
Animal studies consistently show that peripheral inflam-
matory stimuli are associated with functional and molecular
Table 1 Factors reported to be
associated with increased risk
of delirium
(A) Medical setting [69]
Visual impairment Severe illness
Cognitive impairment Dehydration
(B) Post-operative delirium (cardiac surgery) [22]
Cerebrovascular disease Diabetes mellitus
Peripheral vascular disease Preoperative atrial fibrillation
Impaired left ventricular ejection fraction Preoperative cardiogenic shock
Urgent operation Intraoperative hemofiltration
Prolonged duration of surgery High blood transfusion requirement
(C) Post-operative delirium (non-cardiac surgery) [32]
Cognitive impairment Older age
Functional impairment Sensory impairment
Depression Preoperative psychotropic drug use
Psychopathological symptoms Medical comorbidity
Table 2 Medical or surgical conditions in which systemic inflam-
mation is a feature of the pathophysiological process (see references
for details)
Systemic illness
Infection (e.g. sepsis, urinary tract, pneumonia, and abscess)
[123, 144]
Trauma [50, 83], surgery [12, 76]
Burns [71]
Neoplasm (primary, metastasis and paraneoplastic syndrome) [80]
Cardiac
Myocardial infarction [90], cardiac surgery [6]
Haematological
Leukaemia, stem cell transplant [129]
Renal
Renal failure [128]
Hepatic
Hepatitis, cirrhosis, hepatic failure [121]
Orthopaedic
Fractures [140]
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changes in BBB. Increased BBB permeability and altered
expression of tight-junctional proteins were reported in
three different inflammatory models (Table 3). Similarly,
peripheral injection of LPS (the most commonly used
model of acute systemic inflammation) induces, at very
early stages, a cascade of events leading to BBB disruption,
over-expression of adhesion molecules in endothelial
cells, recruitment and infiltration of blood-derived
leucocytes into brain tissue [61, 100, 118] (Table 4). Post-
mortem studies in human brain tissue also show consider-
able correlation between systemic inflammation and
activation of endothelial and perivascular cells [135].
Although neuropathological confirmation of BBB disrup-
tion in human subjects is difficult to obtain, elevated
blood levels of the b subunit of S100 protein (S100-b) can
be considered as an evidence of increased BBB perme-
ability [89]. Thus, several conditions associated with acute
systemic inflammation (e.g. septic shock and cardiac
surgery) are presumably associated with BBB dysfunction
[2, 48, 99]. Likewise, BBB disruption during episodes of
delirium can be inferred from a recent study showing
elevated serum levels of protein S100-b in acutely ill
elderly medical patients with delirium [139]. Also, delirium
during the early phases of septic shock is associated with
leucoencephalopathy in brain magnetic resonance imaging
(MRI), suggestive of BBB breakdown [119]. In addition to
systemic inflammation, other factors affect the BBB
microscopic structure and function, including hypoxia,
ischaemia and pain [93, 104]. Conditions where these fac-
tors occur simultaneously (e.g. sepsis and surgery) are then
more likely to promote the leakage of inflammatory agents
circulating in the plasma through the BBB (Fig. 2).
Reactions of CNS mediated by molecules from systemic
circulation
In the CNS, a diversity of blood-borne molecules, includ-
ing LPS, are able to interact directly with receptors located
on brain endothelial and parenchymal cells. Microglial
cells are particularly capable to detect changes in CNS
environment through a vast number of surface and nuclear
receptors [82, 103]. Thus, in mice CNS, cells lining the
large blood-vessels and microglia express the Toll-like
receptor 4 (TLR4; receptor for LPS). Its activation is a key-
step for the elaboration of a CNS inflammatory response
after administration of peripheral LPS [24]. There is also
evidence that other mediators are implicated in the com-
munication between the periphery and the brain, including
TNF-a and monocyte chemoattractant protein 1 [1, 107,
131] (Table 4). Once activated by receptor–ligand inter-
action, microglia exhibit, over a period ranging from
minutes to few hours, morphological changes alongside
Table 3 Functional and molecular changes in blood-brain barrier following acute systemic inflammatory stimuli
Reference Intervention Results
Huber [68] Formalin (5%) Increased [14C]sucrose uptake at 1 h
Increase in ZO-1 expression at 1 h
k-Carrageenan (3%) Increased [14C]sucrose uptake
Increase in ZO-1 and actin expression
Decrease in occluding expression
CFA (50%)
Huber [67] Pentobarbital sodium ? k-carrageenan (3%) Increased [14C]sucrose uptake at 1, 3, 6 and 48 h
Increased expression of ZO-1 at 1, 3 and 6 h
Decreased expression of occludin at 1, 3, 6, 12 and 48 h
Brooks [17] CFA (50%) At 72 h, decreased occludin expression and increased expression of claudin 3
and 5. No changes in expression of ZO-1 and actin compared to controls
At 72 h increase in [14C]sucrose uptake
Brooks [18] CFA (50%) Increased [14C]sucrose brain uptake at 24 and 72 h
Decreased expression of occludin at 72 h
Increased expression of JAM-1 at 48 h and decreased expression at 72 h
Decreased expression of claudin 5 at 24 h, increased expression at 48 and 72 h
Huber [66] k-Carrageenan (3%) Increased expression of ICAM-1 in cerebral microvessels
No change in systemic proinflammatory cytokines during the early phase
(1–6 h). Early microglia activation (3 h). Increased levels of IL-1 and
IFN-c at 48–72 h
McCaffrey [92] k-Carrageenan (3%) Reduced amount of oligomeric occludin in cerebral microvessels
In each experiment 100 ll of the inflammatory agent was subcutaneously injected into the plantar surface of the right hind paw of female rats
CFA complete Freund’s adjuvant
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with expression of several molecules including MHC class
I, CD45, CD4, ICAM-I, VLA-4, LFA-1 and Fas [79, 82]
(Fig. 2). Following stimulation, some subpopulations of
microglia also express MHC class II and B7 molecules
[98]. These changes are coupled with microglial production
of proinflammatory cytokines (TGF-b1, IL-1b, TNFa,
IGF-1), reactive oxygen species (ROS) and expansion of
microglial population through proliferation of resident cells
and recruitment from adjacent areas or blood [14].
The initial recognition of peripheral inflammatory
stimuli in the BBB is followed by a cascade of events
leading to a coordinated modulation of adjacent cells and
structures of the neurovascular unit [26] (Table 4; Fig. 2).
Endothelial cells, astrocytes, microglia, pericytes and basal
lamina interact through a wide range of mediators includ-
ing cytokines, chemokines and metalloproteinases [23].
Astrocytes are most important in propagating signals gen-
erated in the neurovascular unit to other brain regions
exerting a multimodal control on synaptic transmission,
neuronal excitability and cerebral blood flow [141].
Acute systemic inflammation and neurocognitive
dysfunction
Systemic inflammatory insults are associated not only with
full-blown delirium but they are also implicated in more
subtle neuropsychiatric symptoms. Symptoms similar to but
not meeting the criteria of full delirium have long been
recognized in people treated with recombinant IFN [88] and
occurrence of sub-syndromal delirium has been associated
with adverse outcomes in elderly individuals [27]. In healthy
human subjects experimental treatment with bacterial
Table 4 Animal studies: neuroinflammation following acute systemic inflammation
Author Sample Intervention Results
Gautron [49] 8-week-old rats (250–300 g) LPS i.p. (250 lg/kg) Increased expression of markers of astrocyte activation (STAT3)
in areas lacking BBB at 2 h after treatment, with subsequent
propagation to hypothalamus, cortex, corpus callosum and
hippocampus
Semmler [118] Male rats (250–300 g;
age not specified)
LPS i.p. (10 mg/kg) Increased iNOS expression in the striatum, hippocampus, midbrain
and cerebellum, at 24 h, compared to controls. Increased
number of astrocytes in the cortex, striatum and hippocampus.
Increased expression of apoptotic markers in the cortex,
hippocampus, midbrain and cerebellum
Qin [107] TNF R1/R2?/? mice
(8 weeks old; 20–22 g)
LPS i.p. (5 mg/kg) Increased levels of brain TNF-a mRNA and protein with a peak at
60 min. Elevated levels of TNF-a protein in the brain at
14 days, 21 days and 10 weeks; Microglia activation in cortex,
hippocampus and substantia nigra
TNF-a i.p. (0.25 mg/kg) Increased levels of brain TNF-a mRNA and protein. Increased
synthesis of other pro-inflammatory factors
TNF R1/R2-/- mice
(8 weeks old; 20–22 g)
LPS i.p. (5 mg/kg) TNF-a not detected in the brain
TNF-a i.p. (0.25 mg/kg) TNF-a not detected in the brain
Alexander [1] TNFR?/? mice (8 weeks old) LPS i.p. (0.15 mg) Increased levels of TNF-a and TNFR1 mRNA in the brain,
especially in the hippocampal region
TNF R1-/- mice (8 weeks old) LPS i.p. (0.15 mg) Less apoptosis, less neutrophil infiltration, less astrocytosis, less
iNO mRNA expression compared with TNFR?/? mice
Thompson
[131]
MCP-1?/? mice (20–25 g;
age not specified)
LPS i.p. (5 mg/kg) Increased levels of MCP-1 in the serum and brain up to 24 h
compared to saline controls
Increased levels of IL-1b and TNF-a in plasma, entorhinal cortex,
frontal cortex and hippocampus compared to saline controls
MCP-1-/- mice (20–25 g;
age not specified)
LPS i.p. (5 mg/kg) Increased levels of IL-1b and TNF-a in plasma compared with
LPS-treated MCP-1?/? mice
Increased levels of IL-1b and TNF-a in entorhinal cortex, frontal
cortex and hippocampus compared to saline controls but lower
than in LPS-treated MCP-1?/? mice
Nishioku [100] 8-week-old mice LPS i.p. (20 mg/kg) Increased BBB permeability, microglial activation, structural
alterations in pericytes and basal lamina of the hippocampus
BBB blood-brain barrier, iNOS inducible nitric oxide synthase, LPS i.p. lipopolysaccharide intra-peritoneal, MCP-1 monocyte chemoattractant
protein-1, TNF R1/2 TNF-a receptor 1/2. Whenever appropriate, the genotype of the animals is indicated with -/- (knockout) or ?/?
(wild-type)
Acta Neuropathol
123
endotoxin produces a dose-dependent effect in cognitive
function, emotional state and sleep [96, 110]. Circulating
cytokines are increased by very low dose LPS (0.2 ng/kg)
and these changes have a negative impact in declarative
memory [75]. More recently, a study using functional MRI
documented that injection of peripheral LPS in healthy
volunteers evoked a sustained systemic inflammatory reac-
tion and psychomotor retardation in cognitive tasks and this
correlated with enhanced activity in the left substantia nigra
(SN) [21].
Similarly, the elegant series of rodents’ studies using
LPS, cytokines and surgical procedures established that
peripheral immune stimulation induces an acute and tran-
sient state characterized by sleepiness, anorexia and apathy
together with cognitive impairment [132]. These symptoms
are part of the sickness behaviour syndrome, reproducing
the acute neurobehavioural response to infection. It should
be stated in advance that aspects of the experimental design
used in animal studies have potential confounding factors
affecting the data interpretation [28]. Also, significant
obvious differences exist between the complexity of cog-
nitive, emotional and behavioural repertoires between
rodents and humans. So, rather than being used as com-
prehensive models to mimic the multiple aspects of
delirium, animal experiments can be useful in examining
the pathophysiology underlying particular neurobehavioral
responses to acute systemic inflammation.
Animal experiments using several learning and memory
paradigms have consistently shown that peripheral immune
system activation has a significant impact on cognition. For
example, impairments in memory consolidation of previ-
ously learned tasks and disruption of working memory
were reported in animals following LPS-induced immune
stimulation [105]. Temporary impairment in spatial learn-
ing and memory, coupled with microglial activation and
expression of proinflammatory cytokines, was also descri-
bed in animals undergoing splenectomy. These changes
were not observed in rats devoid of intervention and those
with anaesthesia only [143] (Table 5).
Cognitive changes following acute systemic inflamma-
tion are thought to result from cellular and molecular
synergic interactions in different brain regions and partic-
ularly in the hippocampus. Pro-inflammatory IL-1 has long
been recognized to impair hippocampal-dependent fear
conditioning and to have an important role in neurophysi-
ological processes of memory consolidation, possibly
modulating synaptic plasticity [109]. IL-6 has also been
implicated in hippocampal dysfunction [126] (Table 5). In
contrast, IL-10 seems to counterbalance the effects of IL-1
and IL-6, inhibiting behavioural and cognitive conse-
quences of peripheral inflammation [77, 112] (Table 5).
Likewise, decreased hippocampal decreased expression
of brain-derived growth factor (BDNF) and increased
oxidative stress with mitochondrial dysfunction have also
been implicated in deficits of learning and memory asso-
ciated with neuroinflammation [101, 130]. These data
suggest that the combined action of locally brain produced
ROS, proinflammatory cytokines, metalloproteinases, NO
Fig. 2 Recognition and
propagation of peripheral
immune stimuli in the CNS.
The initial interaction of
circulating inflammatory
mediators (e.g. cytokines and
lipopolysaccharide) with the
neurovascular unit occurs
through a vast number of
receptors and is associated
with an increased paracellular
permeability of the
blood-brain-barrier. In addition
to systemic inflammation, other
factors affect the integrity of
BBB including hypoxia,
ischaemia and pain.
Recognition of peripheral
inflammatory stimuli in the
BBB is followed by a cascade of
events leading to microglia
activation and subsequent
modulation of adjacent cells
including astrocytes and
neurons (represented with
dashed reciprocal arrows)
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Table 5 Animal studies: acute systemic inflammation and neurocognitive dysfunction
Author Sample Intervention Results
Sparkman
[126]
IL-6?/? rats
(3–5 months old)
LPS i.p. (100 lg) Increase in plasma IL-1b, TNF-a, IL-6 and IL-10
Impairment performance in a matching-to-place task in the water maze
at day 2 after compared with saline-injected rats
Increased expression of IL-1b and TNF-a in the hippocampus
IL-6-/- rats
(3–5 months old)
LPS i.p. (100 lg) Increase in plasma IL-1b, TNF-a, IL-6 and IL-10
No impairments in performance in the water maze compared with controls
No increased expression of IL-1b and TNF-a in the hippocampus
Tanaka
[130]
Male rats (age and
weight not specified)
Intra-hippocampal LPS
for 5 consecutive days
(20 lg/day)
Increased expression of IL-1 and TNF-a at 2 h co-localized with microglia
After sub-acute treatment with LPS for 5 days animals presented memory
and learning deficits in a passive avoidance task, long-term activation
of microglia and decreased expression of BDNF and TrkB
Noble
[101]
10- to 12-week-old mice
(35–40 g)
LPS i.p. (250 lg) Memory impairment in a Y-maze test
Increased ROS and NO production associated with GSH depletion in brain
mitochondria
Wan [143] 90-day-old rats
(300–350 g)
Anaesthesia only No differences from control rats. No glial activation
Splenectomy Impaired cognitive performance, microglial activation and increased
production of IL-1b mRNA in the hippocampus at post-operative days
1 and 3
Krzyszton
[77]
IL-10?/? mice
(3 and 12 months old)
LPS i.p. (10 lg) Motor performance and learning not different from controls receiving saline
Increased levels of IL-1b, TNF-a, and IL-6 in cerebellum, cortex,
hippocampus and striatum compared to controls
IL-10-/- mice
(3 and 12 months old)
LPS i.p. (10 lg) Deficits in motor performance and learning compared with animals injected
with saline
Increased levels of IL-1b, TNF-a, and IL-6 in cerebellum, cortex,
hippocampus and striatum compared to IL-10-/- animals receiving
saline, with markedly higher levels than in LPS-treated IL-10?/? animals
in 3 of 4 brain regions
Lee [81] 25–30 g male mice
(age not specified)
LPS i.p. (250 lg/kg) Cognitive impairment in passive avoidance test and water maze test
Increased levels of Ab1-42 and decreased levels of Ab1-40 in the
hippocampus
Increased expression of APP, BACE and C99 with increased activity
of b and c-secretase in the cortex and hippocampus
Increased number of activated astrocytes and apoptotic cells in the
hippocampus
Richwine
[112]
IL-10?/?
(3-month-old mice)
LPS i.p. (10 lg) Reduced locomotor behaviour at 4 h and recovering to 72% of controls
at 24 h
Increased expression of IL-1, IL-6 and TNF-a in the hippocampus,
hypothalamus, cortex and cerebellum
Reduced expression of hippocampal BDNF
IL-10-/-
(3-month-old mice)
Saline i.p. Lower levels of BDNF in the hippocampus compared to saline-injected
IL-10?/? mice
LPS i.p. (10 lg) Reduced locomotor behaviour at 4 h with 35% of controls at 24 h
Cytokine levels significantly increased compared with LPS-treated
IL-10?/? mice at 4 h
Expression of hippocampal BDNF significantly lower than LPS-treated
IL-10?/? mice
Impaired performance in a matching-to-place task in the water maze at 24 h
APP amyloid precursor protein, BACE b-site APP cleavage enzyme, BDNF brain-derived neurotrophic factor, GSH reduced glutathione, LPS
lipopolysaccharide, ROS reactive oxygen species. Whenever appropriate, the genotype of the animals is indicated with -/- (knockout) or ?/?
(wild-type)
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and chemokines induce functional changes in neurons,
affecting processes such as synaptic plasticity and long-
term potentiation, and can impair learning and memory
[91].
There is evidence that microglia and astrocyte activation
by peripheral immune challenge can promote Bax/Bcl-2
imbalance and affect intraparenchymal brain cell survival
[118]. In fatal cases of septic shock, Sharshar et al. [120]
found neuronal and glial apoptosis within the cerebral
autonomic centres in human brains, which correlated with
the expression of endothelial inducible nitric oxide syn-
thase (iNOS). Lee et al. [81] suggested that the activation
of amyloidogenesis associated with neuroinflammation
could be an important mechanism implicated in the apop-
totic neuronal death and neurocognitive dysfunction
induced by systemic immune stimuli (Table 5). The cas-
cade of events occurring within the CNS following
peripheral immune stimulation can affect neuronal viability
even at long term. Thus, a single exposure to systemic LPS
or TNF-a induced a significant loss of dopaminergic neu-
rons in the SN first observed at 7 months (23% loss) and
showing increasing severity at 10 months after the insult
(47% loss) [107].
Overall, these data demonstrate that acute exposure to
systemic inflammation elicits a neurocognitive clinical
syndrome analogous to delirium coupled with an underly-
ing neuroinflammatory reaction affecting synaptic and
neuronal function. As the synthesis of acetylcholine is
particularly sensitive to homeostatic changes in the brain,
neuroinflammation promotes a cholinergic deficit with
associated imbalances in other neurotransmitters including
dopamine, serotonin and norepinephrine [64]. The current
scientific knowledge cannot fully explain the exact mech-
anisms by which these structural, functional and neuro-
chemical changes are translated into cognitive, behavioural
and emotional symptoms. Data from anaesthetics demon-
strate that some core symptoms of delirium (e.g. impaired
consciousness) likely involve changes in dynamic aspects
of neuronal activity affecting brain’s ability to integrate
information through functional disconnection between
different anatomical structures [3]. Also, distinct clinical
features may arise due to impairment of brain areas known
to be the neuroanatomical substrates of alertness, aware-
ness and attention [149]. It is also possible that the
neuroinflammatory pathway may only be responsible for
some specific symptoms of delirium.
Effects of acute systemic inflammation in the brain:
influence of ageing and neurodegeneration
Individuals with advanced age and/or with prior cognitive
impairment (including dementia) are at greater risk of
developing delirium. There is also increasing evidence that
the occurrence of delirium predicts adverse cognitive out-
comes at long term in subjects with or without pre-existing
dementia [46, 86]. This suggests that delirium and
dementia share overlapping pathophysiological features
which arise in the context of the ageing process, the
common risk factor to both conditions. It is therefore of
major interest to explore the influence of ageing and neu-
rodegenerative conditions in the CNS response to systemic
inflammation.
Effects of acute systemic inflammation in the ageing
brain
Several aspects of the innate and cellular immunity are
affected as age increases, a process known as ‘‘immu-
nosenescence’’ [52]. Elderly individuals show a weaker
adaptive immunity rendering them more prone to infection
and less responsive to vaccination or experimental treat-
ment with LPS [20, 41]. At the same time, the ageing
process is associated with a sustained two- to fourfold
increase in baseline levels of circulating inflammatory
mediators including cytokines and acute phase proteins
[74].
Cognitive performance is generally preserved in human
normal ageing apart from a slowed processing speed and
impairment in spatial memory [148]. Several neuropatho-
logical, cellular and molecular changes are associated with
ageing, including a decline in brain volume and weight, loss
of synaptic density and plasticity as well as variable chan-
ges in dendritic branching [136]. Studies in cognitively
intact elderly show a strong positive correlation between
age and altered tau protein metabolism with accumulation
of neurofibrillary tangles and a variable deposition of
corpora amylacea, argyrophilic grains, neuromelanin, and
lipofuscin in various brain regions [72, 95]. Equally
important is the finding of an increased number of activated,
enlarged or dystrophic microglia in the aged brain of non-
demented subjects paired with immunophenotypic changes
such as up-regulation of MHC class II [47]. While it
remains controversial whether these cells represent an
activated rather than a senescent state, it is clear that
microglial cells undergo age-related morphological and
functional changes which can induce a pro-inflammatory
environment in the aged brain [13]. It is likely that this
microglial ‘‘primed’’ state with increased reactivity is the
consequence of several factors including chronic accumu-
lation of minor insults resulting in DNA damage and in the
production of advanced glycation end products of tissue and
cell surface proteins [36].
Neuropathological evidence linking neuroinflammation
to clinical signs of brain dysfunction is illustrated by a case-
report in which widespread neuroinflammatory changes
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induced by relapsing polychondritis were responsible for
clinical features of Dementia with Lewy bodies [54]. Sim-
ilar reports are useful to explore the neuropathological
correlates of chronic, but not acute, systemic inflammatory
conditions in an aged non-degenerative brain. Thus, animal
studies remain the only way to document in detail how the
ageing process can influence the CNS response to acute
systemic inflammation (Fig. 3).
As in humans, brains of aged mice devoid of neurode-
generative disease show an increased expression of genes
associated with heightened microglial reactivity [108].
Following peripheral administration of LPS, old mice show
a delayed recovery from sickness behaviour, compared to
adult animals, reflecting an exaggerated and protracted
neuroinflammatory response [51] (Table 6). These findings
were replicated following administration of intracerebro-
vascular LPS [65] which, by excluding any potential
cytokine amplification at the periphery, support that ageing
is associated with increased CNS immune responsiveness
(Table 6). Chen et al. [25] reported that old mice consis-
tently showed higher basal levels of microglia density and
inflammatory cytokines in the hippocampus compared with
their young adults counterparts. Peripheral inoculation of
LPS increased hippocampal expression of cytokine mRNAs
(IL-1, IL-6, TNF-a) in both groups (old and young adults),
but significantly more in the old mice. Furthermore, old
mice treated with LPS showed the most severe disruption in
hippocampal capacity to integrate new information in
relation to any of the other groups. In another study, Henry
et al. [55] reported an increased microglial expression of
MHC II in aged mice, a phenotype indicating a primed or
reactive state (Table 6). Following LPS peripheral chal-
lenge, primed microglia were activated to a greater extent
than MHC II-negative microglia and were highly respon-
sible for the exaggerated production of IL-1b. These
findings are in line with those of Richwine et al. [111] who
found higher steady-state expression of pro-inflammatory
cytokines and decreased expression of neurotrophic factors
in the hippocampus of aged mice compared with adults
(Table 6). This was associated with increased vulnerability
of CA1 neurons to LPS-induced neuroinflammation as
shown by structural changes with decreased dendrite com-
plexity compared to adult controls. Interestingly, even
minor surgical trauma was associated with increased IL-1b
hippocampal expression of aged but not adult animals on
the first post-operative day [113] (Table 6).
Acute systemic inflammation in dementia
Dementia is a syndrome characterized by a progressive and
irreversible decline in multiple cognitive domains. This is
manifested by memory impairment and other associated
cognitive deficits (e.g. aphasia, apraxia, agnosia, distur-
bance in executive functioning) which cause significant
interference in social and occupational functioning [5].
Patients with dementia represent up to 42% of all
admissions in acute medical wards mainly due to urinary
tract or respiratory infections [115]. Delirium complicates
Fig. 3 The effects of acute
systemic inflammation in the
brain: the influence of ageing
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24–89% of hospitalizations for elderly patients with
dementia predicting poor cognitive and functional out-
comes [10, 44, 94]. Therefore, differentiating delirium
from pre-existing dementia is clinically relevant and has
been recommended as a routine practice [16]. Classically,
delirium and dementia have been differentiated based on
clinical features (impaired versus clear consciousness) and
natural course (rapid onset and fluctuating versus pro-
gressive onset and stable). Still, there is a substantial
clinical overlap between the two conditions and the crucial
issue in most cases is to identify and remove the reversible
components of the clinical picture. Delirium superimposed
in dementia is associated, as in non-demented patients,
with deregulation of neurotransmitter systems [137]. Also,
there is no strong evidence that delirium has distinct fea-
tures when occurring in patients with prior dementia [134].
However, recent studies suggest that level of consciousness
and hyperactive motor features can be more frequently
seen among delirious demented patients than in non-
demented patients with delirium [15, 38].
Chronic neuroinflammatory events are known to play an
important role in dementia, particularly in AD. In fact, one
of the hallmarks of AD is presence of activated microglia
and reactive astrocytes in Ab plaques and neurofibrillary
Table 6 Animal studies: the effects of acute systemic inflammation in the ageing brain
Author Sample Intervention Results
Godbout
[51]
3- to 6-month-old
rats
Saline i.p.
LPS i.p. (10 lg) Increased levels of inflammatory cytokines in the brain
20- to 24-month-old
rats
Saline i.p. Gene transcriptional profile suggestive of primed microglia and increased inflammation
in the brain
LPS i.p. (10 lg) Prolonged sickness behaviour and exaggerated production of brain inflammatory
cytokines compared with younger animals
Huang [65] 3- to 4-month-old
mice
Saline icv
LPS (10 ng) icv Increased levels of IL-1b, IL-6 and TNF-a in cerebellum and hippocampus
20- to 24-month-old
mice
Saline icv Increased expression of reactive microglial markers compared to adults
LPS (10 ng) icv Protracted sickness behaviour associated with prolonged cytokine overexpression
compared to adults
Chen [25] 3- to 4-month-old
mice
Saline i.p.
LPS i.p.
(0.33 mg/kg)
Increased levels of inflammatory cytokine mRNA in hippocampus
22- to 24-month-old
mice
Saline i.p. Increased number of microglial cells and higher levels of IL-1b in hippocampus
compared to adult mice treated with saline
LPS i.p.
(0.33 mg/kg)
Higher levels of inflammatory cytokine mRNA in hippocampus compared to adult mice
treated with LPS. Deficits in spatial working memory
Richwine
[111]
3- to 6-month-old
mice
Saline i.p.
LPS i.p.
(0.33 mg/kg)
Increase in hippocampal expression of IL-1b, IL-6 and TNF-a mRNA peaking at 4 h
22- to 24-month-old
mice
Saline i.p. Increased expression of MHC II mRNA and lower expression of NGF and BDNF in the
hippocampus compared to adults
LPS i.p.
(0.33 mg/kg)
Higher levels of hippocampal pro-inflammatory cytokines compared to adults.
Decreased arborisation of apical dendritic tree compared to old controls
Rosczyk
[113]
4- to 6-month-old
mice
Minor abdominal
surgery
Increased levels of IL-1b mRNA in hippocampus of aged mice
23- to 25-month-old
mice
Henry [55] 3- to 4-month-old
mice
Saline i.p.
LPS i.p.
(0.33 mg/kg)
Increased expression of IL-1b and IL-10 mRNA in microglia
18- to 20-month-old
mice
Saline i.p. Increased expression of MHC II in microglia compared to adults
LPS i.p.
(0.33 mg/kg)
More pronounced increased in IL-1b and IL-10 than in adult microglia
BDNF brain-derived neurotrophic factor, icv intracerebroventricular, LPS lipopolysaccharide, MHC major histocompatibility complex,
NGF nerve growth factor
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tangles together with a broad variety of inflammatory
mediators before the development of extensive tau-related
neuropathology and brain atrophy [120]. Interaction of Ab
with microglial cell surface receptors, in the presence of
synergic molecules such as complement cascade proteins,
induces the activation of microglia with subsequent
phagocytosis of amyloid and production of inflammatory
cytokines by these cells [39]. Interestingly, the LPS
receptor CD14 interacts with fibrillar Ab suggesting that a
structural mimicry exists between aggregated Ab fibrils
and pathogenic-associated microbial patterns [85]. There is
evidence that microglia activation leads to a reduction in
Ab plaques supporting their neuroprotective role [30].
However, reactivity of microglia and astrocytes against Ab
can promote or exacerbate the neuropathological changes
of AD [43, 97]. In fact, inflammatory conditions can impair
microglial capacity for internalization of amyloid precursor
protein (APP) peptides [142] and affect the expression and
function of APP secretases [116] favouring the accumula-
tion of Ab fibrils. Similarly, microglia-derived IL-1b and
IL-6 can induce tau hyperphosphorylation through activa-
tion of the p38-MAPK and cyclin-dependent kinase 5
(cdk5), respectively [73].
In addition to up-regulation of a broad variety of
inflammatory mediators in the AD brain, serum levels of
inflammatory markers have been associated with a risk
of cognitive decline in several cross-sectional and longi-
tudinal studies, albeit with conflicting results [4, 117].
Moreover, impaired BBB function has been implicated in
several pathogenic cascades in AD [9] presumably ren-
dering AD patients more prone to detrimental effects of
acute systemic CNS inflammation. To clarify this, few
attempts have been made to explore the impact of acute
systemic inflammation on the natural course of AD. In a
study by Holmes et al. [62], acute systemic inflammatory
events were associated with a twofold increase in the rate
of cognitive decline over a 6-month period. There was no
association between the occurrence of those episodes with
delirium (assessed at 2, 4 and 6 months) [62]. This could
have resulted from the under-recognition of delirium in the
sample and to the mild nature of majority of the acute
systemic inflammatory events. Thus, it seems that acute
systemic inflammation interferes with the natural course of
AD, even if it is not severe enough to elicit delirium
symptoms. Additional data on this topic is provided by
Higuchi et al. [60] who, although not using specific
instruments to evaluate delirium, found elevated blood
levels of IL-1b in AD patients early before and during
periods of agitation. Clearly, longitudinal studies docu-
menting the immediate impact of acute systemic
inflammatory episodes on the mental state of patients are
needed.
Further insight about the effect of acute systemic
inflammation in the pathophysiology of dementia is pro-
vided by pre-clinical research. Animals previously infected
with murine prion disease as a model of chronic neurode-
generation have microglia with morphologic changes
typical of activation, with altered morphology and upreg-
ulation of surface markers, but without elevated levels of
cytokines or iNOS [29]. Intraperitoneal LPS injection
induces an intense neuroinflammatory response in animals
with ongoing neurodegeneration which is associated with
neuronal death as demonstrated by increased number of
TUNEL-positive cells showing apoptotic morphology [29].
Transgenic APP mouse models of AD are also useful to
explore the effects of LPS treatment in neuroinflammation
and amyloid deposition. While studies consistently dem-
onstrate that LPS administration to amyloid-depositing
transgenic mice results in expected neuroinflammatory
changes (microglia activation, and increase of inflamma-
tory mediators), findings regarding amyloid deposition are
conflicting. Thus, some studies reported increased deposi-
tion of Ab in mice brain parenchyma following treatment
with LPS [106, 122], whereas others have demonstrated a
decrease in Ab load following LPS exposure, supporting a
role for microglia in Ab removal [34, 57, 58]. With disease
progression, expression of microglial Ab-binding receptors
and Ab-degrading enzymes is reduced and coupled with
over-expression of pro-inflammatory cytokines. These
changes are likely to impair Ab processing and removal by
microglia, potentially contributing to accelerate the disease
course [59].
In summary, there are clinical and neuropathological
evidences suggesting that pre-existing dementia signifi-
cantly increases the susceptibility of CNS to the deleterious
effects of acute systemic inflammation. Inversely, acute
systemic inflammation can aggravate the pathophysiologi-
cal changes associated with the ongoing neurodegenerative
process. Although these findings have not been typically
conceptualized as being central to delirium, they support an
aetiological role for the neuroinflammatory pathway both
in delirium and dementia, proving a pathophysiological
explanation for the intimate relation between the two
conditions.
Perspectives on prevention and treatment of delirium
Management of delirium involves the early identification and
immediate removal of precipitating factors complemented
with supportive measures and, in general, symptomatic use of
neuroleptic medication is not recommended as the primary
management of delirium. In some patients with hyperactive
symptoms, such as agitation or hallucinations, haloperidol
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remains the preferred drug but it should be used cautiously
[16]. In fact, in elderly subjects with dementia, the use of
anti-psychotics to control symptoms of agitation has been
associated with increased mortality [7]. So, considerable
interest exists whether the evidence reviewed in this paper can
bring new approaches for the prevention and management of
delirium. In this regard, some agents with anti-inflammatory
action were useful to reduce LPS-induced microglial/astro-
cyte activation, production of pro-inflammatory mediators
and facilitating recovery from neurobehavioural symptoms
[11, 56, 84, 118]. Likewise, in models of experimental sep-
sis there is evidence that blockage of C5a, a small peptide
derived from complement activation, can prevent BBB
breakdown [45]. It remains to be determined how these find-
ings can be applied to humans. Nevertheless, development of
pharmacological strategies that can modulate the neuroin-
flammatory pathway may well offer new therapeutic tools to
be used in the management of delirium.
Conclusions
Delirium is a complex and dynamic condition character-
ized by non-linear interactions among aetiologically
distinct factors and by graded and continuous changes in
cognitive, behavioural and emotional symptoms. Clini-
cally, it is often difficult to recognize and to differentiate
from other psychiatric disorders, as it involves subtle
changes in a wide range of neurocognitive and psycho-
motor domains. Not surprisingly, delirium has resisted to
Fig. 4 The neuroinflammatory pathway of delirium. The majority of
conditions associated with delirium are characterized by significant
aetiological and pathophysiological heterogeneity with complex
interactions of multiple factors (systemic inflammation, dehydration,
electrolytic imbalance, pharmacological agents, ischaemia, hypoxia,
pain, etc.). Activation of the systemic inflammatory response is a
feature of several acute medical or surgical disorders, particularly
when involving tissue destruction and/or infection. In such cases,
numerous molecules (e.g. lipopolysaccharide and pro-inflammatory
cytokines) circulating in the bloodstream (represented as A1, A2, Ax)
elicit a cascade of functional and structural changes within the
neurovascular unit leading to the activation of microglial cells and
astrocytes. The acute neuroinflammatory reaction affects physiolog-
ical processes implicated in neuronal and synaptic function with
consequent neurochemical disturbances and functional disconnection
between different anatomical structures. These neurobiological
changes underlie acute and transient failure of high integrative
cognitive, behavioural and emotional functions as seen in delirium.
When present, other factors (e.g. dehydration, electrolytic imbalance,
pharmacological agents, ischaemia, hypoxia, pain, etc., represented as
Z1, Zx) while not directly activating a systemic inflammatory
response, can exert synergic effects with the neuroinflammatory
pathway through alternative pathophysiological routes. The contri-
bution of the neuroinflammatory pathway to promote the symptoms of
delirium is likely to be especially relevant in elderly subjects or in
patients with prior dementia. As discussed in the text, several
pathophysiological changes associated with both conditions render
the brain more vulnerable to the deleterious effect of acute systemic
inflammation (represented with dashed arrows). BBB blood-brain
barrier, BDNF brain-derived growth factor, CNS central nervous
system, ROS reactive oxygen species
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the formulation of consistent etiopathogenic models able to
integrate the already identified risk factors with their
underlying clinical correlates.
In this review we have attempted to provide a compre-
hensive perspective about the contribution of the neuro-
inflammatory pathway in the pathogenesis of delirium. Thus,
there is compelling evidence that the presence of peripheral
immune signals culminates, through a complex system of
communication involving the BBB, in functional and
structural changes in brain parenchymal cells, including
microglia, astrocytes and neurons. These neuroinflammatory
changes are associated with acute onset of cognitive,
behavioural and emotional disturbances. While studies in
humans could provide the best evidence linking acute sys-
temic inflammation to the specific symptoms of delirium, the
research in this field remains very scarce. So, despite all the
limitations, animal models are useful to evaluate the neuro-
pathological correlates of acute psychomotor and cognitive
disturbances associated with acute systemic inflammation.
By gathering data from both sources it is apparent that a
neuroinflammatory response is an important event associated
with delirium whenever the subject is exposed to a diverse
range of peripheral conditions, especially when involving
infection, tissue destruction and systemic inflammation. Brain
homeostasis, neurotransmission and neurophysiological
functions of several regulatory centres in the brain can be
compromised by the neurotoxic effect of cytokines, ROS, NO
and other inflammatory mediators, generated mainly by
microglial and astrocytic cells. Predictably, when such events
occur, dysfunction of cerebral cortical areas and sub-cortical
structures is likely to result in a reduced capacity to interact
with the environment and to integrate stimuli within the
cognitive experience. This provides a plausible neurobio-
logical rational supported by a temporal association linking
neuroinflammation phenomena to the failure of high inte-
grative cognitive, behavioural and emotional functions
observed in delirium (Fig. 4).
This is further pronounced in elderly subjects and in
patients with dementia. As discussed, in both cases several
regulatory networks involved in neuroprotection are charac-
teristically dysregulated and microglial cells are overactivated
in baseline conditions. It is, therefore, likely that people with
advanced age and/or neurodegenerative disorders would be at
increased risk to develop delirium because, even when other
factors are excluded, the neuroinflammatory response would
be amplified due to a combination of primed microglia,
increased production of pro-inflammatory mediators and
decreased level of protective mechanisms (Fig. 4). Another
important question is whether neuroinflammatory changes co-
occurring with delirium have a role in the development of
neurodegeneration and cognitive impairment at long term. As
shown, evidence from clinical and animal studies reveals that
beyond the acute phase, acute systemic inflammation can
elicit a sustained dysregulation in neuroinflammatory events
potentially aggravating pre-existing neurodegeneration and
cognitive decline.
The evidence about the intricate neuroinflammatory
processes underlying acute neurocognitive and behavioural
symptoms following systemic inflammation insults provide
powerful insight for the formulation of a comprehensive
etiopathogenic model of delirium. In the context of a
multifactorial, complex and dynamic model, the neuroin-
flammatory pathway can be a major process underlying
delirium when the individual is exposed to an acute sys-
temic inflammatory condition (e.g. infection or surgery).
This model does not exclude, of course, the contribution of
other factors known to be relevant to the syndrome such as
hypoxia, dehydration, electrolytic imbalance and pharma-
cological agents. Presumably, the synergic interaction
among these factors can result in a complex and simulta-
neous acute failure of several physiological pathways
involved in brain homeostasis.
The progressive understanding of the fundamental
neurobiological processes underlying delirium will allow a
more precise definition and classification of this syndrome
looking behind its confusing plethora of symptoms and
taking into account its pathogenesis. This knowledge is
also crucial to guide the search for specific and sensitive
biomarkers enabling the risk stratification, the diagnosis at
the pre-symptomatic stage, monitoring the clinical evolu-
tion and predicting the clinical outcome. Ultimately, this
will also have implication on the development of more
effective approaches to prevent the occurrence of delirium
and slow the progression or retard the clinical manifesta-
tions of neurodegenerative disorders.
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